Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Telix Pharmaceuticals reported Q2 2026 group revenue of US$247 million (up 7% QoQ, 21% YoY) with Precision Medicine revenue reaching US$202 million (up 30% YoY). The company achieved key regulatory milestones including FDA alignment on TLX591-Tx Phase 3 trial progression and near-completion of BiPASS patient enrollment. FY 2026 revenue guidance remains on track to exceed US$1 billion. Telix also entered a strategic collaboration with Regeneron and completed a convertible bond refinancing.